Threat actors are operationalizing AI to scale and sustain malicious activity, accelerating tradecraft and increasing risk for defenders, as illustrated by recent activity from North Korean groups ...

With global demand for entry-level developers, analysts, and tech-enabled professionals continuing to rise, beginners are ...

Overview: Developers use high-performance languages such as C++ and Rust to build AAA titles and competitive games.Cross-platform engines simplify development b ...

COBOL is in the headlines again, and this time it is because of artificial intelligence (AI) – sparking conversations with tools emerging that claim t.

IBM or International Business Machines Corp had its worst day on stock market in more than 25 years on Monday, February 23.

The deadly mass shooting at a school in British Columbia came as Canadian authorities face significant obstacles in rolling out a nationwide firearms buyback that is mired in practical and logistical ...

A simple brain-training program that sharpens how quickly older adults process visual information may have a surprisingly powerful long-term payoff. In a major 20-year study of adults 65 and older, ...

Beijing, Moscow and shaken American allies are seeking new warheads as President Trump ends more than a half century of nuclear arms control with Russia. President Trump meeting with President ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Java ranked third in the Tiobe Index for January 2026 at 8.71%, holding steady behind Python and C and just ahead of C++. Tiobe named C# its Programming Language of the Year for 2025 after the largest ...

The Pentagon is looking to launch a new Enterprise Command and Control Program Office in a move that would consolidate and refresh its long-standing efforts to provide common operating panes and ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...